KLRK1 and Friedreich ataxia: The study defines the need for additional testing of therapeutics that inhibit NKG2D–NKG2D-L interactions to block immune-mediated HSPC clearance, an approach that could buy critical time for FA patients pursuing autologous gene therapy or alloSCT.